On September 2, 2020 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that Michael Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fireside chat at Baird’s 2020 Global Healthcare Conference and at the Morgan Stanley 18th Annual Global Healthcare Conference (Press release, Karyopharm, SEP 2, 2020, View Source [SID1234564318]). Details regarding these September conferences are below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird’s 2020 Global Healthcare Conference
Date: Wednesday, September 9
Time: 10:15 AM ET

Morgan Stanley’s 18th Annual Global Healthcare Conference
Date: Tuesday, September 15
Time: 5:00 PM ET

A live webcast of the fireside chats can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source A replay of the webcast will be archived on the Company’s website for 90 days following each fireside chat.

On September 2, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that the company’s management will participate in the following investor conferences during the month of September 2020 (Press release, Affimed, SEP 2, 2020, View Source [SID1234564315]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2020 Wells Fargo Virtual Healthcare Conference (September 9-10, 2020)
Date: Wednesday, September 9, 2020
Presentation Time: Fireside chat with Dr. Jim Birchenough at 8:00 a.m. Eastern Time

Citi’s 15th Annual BioPharma Virtual Conference (September 8-11, 2020)
Date: Wednesday, September 10, 2020
Affimed will host meetings with investors at the conference

Cantor Fitzgerald Virtual Global Healthcare Conference 2020 (September 15-17, 2020)
Date: Thursday, September 17, 2020
Presentation Time: 12:40 p.m. Eastern Time

Oppenheimer Fall Healthcare Life Sciences and Med Tech Summit (September 21-23, 2020)
Date: Monday, September 21, 2020
Presentation Time: 3:20 p.m. Eastern Time
Location: Virtual

Webcasts of each presentation may be accessed on Affimed’s website at View Source For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at [email protected] or phone at (917) 436-8102.

On September 2, 2020 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, reported that members of management will participate in several upcoming conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird Global Healthcare Conference. Fireside chat on Wednesday, September 9, 2020 at 12:15 p.m. ET.
Morgan Stanley Global Healthcare Conference. Fireside chat on Monday, September 14, 2020 at 1:30 p.m. ET.
BofA Global Healthcare Conference. Fireside chat on Thursday, September 17, 2020 at 10:50 a.m. BST.
Stifel Immunology & Inflammation Summit. Panel on Thursday, October 1, 2020 at 11:00 a.m. ET.
Additional information regarding these events will be available on the Company’s website at www.argenx.com.

On September 2, 2020 Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, reported that Laurence Reid Ph.D., Chief Executive Officer of Decibel, will present at Citi’s 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020 at 1:10pm ET (Press release, Decibel Therapeutics, SEP 2, 2020, View Source [SID1234564312]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 2, 2020 Orca Bio and Lyell Immunopharma reported a research partnership to jointly identify next generation T cell therapies that will combine precision purification T cell technologies from Orca Bio with the scientific expertise in T cell biology from Lyell to generate potentially synergistic therapeutic solutions for solid tumors (Press release, ORCA Biosystems, SEP 2, 2020, View Source [SID1234564311]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lyell Immunopharma has brought together an unrivaled scientific team focused on advancing the science of therapeutic T cells, including the role of T cell differentiation. Orca Bio has developed T cell therapies for patients with blood diseases while also streamlining the commercial manufacture of high-precision cell therapies using OrcaSort, an ultra-fast, clinically compatible cell sorter.

The ability to produce optimal starting cell populations is one of many continuing challenges in the development of curative T cell therapies. Evidence from current generation cell therapies suggest that the proportion of cell types and their stages of differentiation may impact the safety and efficacy of T cell therapies. Together, the companies aim to mitigate this challenge by utilizing their proprietary technologies to effectively treat solid tumor cancers.

"Lyell Immunopharma is focused on developing curative T cell therapies for solid tumor cancers by defining starting cell preparations and modulating T cells, so they are functional in the immunosuppressive tumor microenvironment," said Nick Restifo, M.D., Executive Vice President of Research for Lyell Immunopharma. "This collaboration with Orca Bio provides the potential to more efficiently define starting cell preparations, which I believe could lead to more effective T cell therapies."

"Orca Bio has developed extremely pure doses of stem and immune cells that can be precisely formulated to treat cancers," said Ivan Dimov, PhD, co-founder and CEO of Orca Bio. "By combining our scientific expertise with that of Lyell Immunopharma, and by applying our specialized manufacturing platform, we aim to create the scalable production of adoptive T cell therapies that can reach patients with unprecedented speed."

Lyell Immunopharma and Orca Bio will each continue to pursue programs independently and through their other partnerships.